Prostate Cancer Reagents

Home > Featured Products > Oncology Research > Prostate Cancer

Prostate cancer is the most common non-skin cancer in men. Biomarker-driven research — from PSA-based screening to PSMA-targeted theranostics — is transforming diagnosis and treatment. abinScience provides antibodies, proteins, and kits targeting PSA/KLK3, PSMA/FOLH1, androgen receptor (AR), TMPRSS2-ERG, and STEAP1 for prostate cancer research. RUO

Key Biomarkers & Targets

PSA / KLK3

Prostate-Specific Antigen

The most widely used prostate cancer screening biomarker. 60+ antibodies and recombinant proteins for ELISA and immunoassay development.

Antibodies • Proteins

PSMA

FOLH1 / GCPII

Overexpressed in prostate cancer; therapeutic and imaging target (lutetium-177 PSMA, 68Ga-PSMA PET). 47 antibodies and biosimilar proteins.

Antibodies • Proteins • Biosimilars

Androgen Receptor

Central driver of prostate cancer; target of enzalutamide, abiraterone. Reagents for AR signaling, splice variants (AR-V7), and resistance studies.

Antibodies

TMPRSS2-ERG

Gene Fusion

Present in ~50% of prostate cancers. Anti-ERG (400+) and anti-TMPRSS2 (13) antibodies for fusion detection by IHC and WB.

Antibodies • Proteins

STEAP1

Six-Transmembrane Protein

Emerging ADC target with high prostate cancer specificity. 16 STEAP-family antibodies and recombinant proteins available.

Antibodies • Proteins

PD-L1 / PTEN

Immune & Tumor Suppressor

PD-L1 for immunotherapy stratification; PTEN loss associated with aggressive disease and PI3K/AKT pathway activation.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for Prostate Cancer

PSA Immunoassay DevelopmentAnti-PSA antibodies with ELISA validation and recombinant PSA proteins. Contact us for pairing recommendations.

PSMA Theranostics SupportAnti-PSMA/FOLH1 antibodies and recombinant ectodomains for radioligand therapy R&D, PET tracer development, and ADC drug screening.

AR Pathway ProfilingAntibodies targeting AR, AR-V7, and downstream effectors for studying castration-resistant prostate cancer (CRPC) mechanisms and drug resistance.

Protein–Antibody–Kit WorkflowSame target as recombinant protein, detection antibody, and ELISA kit from one manufacturer for streamlined assay development.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

PSA screening assay development: Anti-PSA antibodies with ELISA and FCM validation, plus recombinant PSA proteins, available for immunoassay development.
PSMA-targeted therapy R&D: Research-grade PSMA biosimilar proteins with ELISA and FACS validation available for comparability and binding studies.
CRPC resistance mechanisms: Profile AR, AR-V7 splice variant, and PTEN/PI3K/AKT signaling with our antibodies (WB, IHC) to study enzalutamide and abiraterone resistance.
Fusion gene detection: Use anti-ERG antibodies (IHC) as a surrogate marker for TMPRSS2-ERG fusion status in prostate cancer tissue specimens.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you offer matched PSA antibody pairs for ELISA?

Yes. Anti-PSA/KLK3 monoclonal clone SAA0506 with ELISA, Blocking, and FC validation (available in FITC/APC/PE/PerCP conjugates). Polyclonal antibodies and recombinant PSA proteins also available.

Which PSMA antibodies work for flow cytometry?

Research-grade PSMA/FOLH1 biosimilar antibodies (e.g., pasotuxizumab) with ELISA and FACS validation. Anti-PSMA polyclonal antibodies also available.

Do you have AR-V7 splice variant reagents?

We offer anti-AR polyclonal and monoclonal antibodies. See product pages for validated applications and species reactivity.

What reagents are available for STEAP1 ADC development?

We carry anti-STEAP1 antibodies and recombinant STEAP1 proteins for target validation, cell-surface expression profiling, and binding characterization in ADC research.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.